Evidence map›Paper›PMID 34057284›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2022

Patterns of tau pathology identified with

William Charles Kreisl, Patrick J Lao, Aubrey Johnson, Zeljko Tomljanovic, Julia Klein, Krista Polly, Benjamin Maas, Krystal K Laing, Anthony G Chesebro, Kay Igwe and 9 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03389100 (Tau Positron Emission Tomography), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03389100 phase2enrolling by invitationnot on this map

Tau Positron Emission Tomography (PET) Imaging in the Northern Manhattan Study of Metabolism and Mind (NOMEM) With 18F-MK6240.

TypeinterventionalSponsorColumbia UniversityRan2018 to 2026Enrolled600ConditionsDiabetes Mellitus, Type 2, Pre-diabetesArms18F-MK6240 injection
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 17 citations in OpenAlex.

  1. Evaluation of tau deposition usingAlzheimer's research & therapy · 2022
    Trial
  2. Observational
  3. Association of type 2 diabetes treatment status with in vivo biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Review
  9. Article
  10. [Synapse (New York, N.Y.) · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Test-retest performance of [Imaging neuroscience (Cambridge, Mass.) · 2024
    Article
  15. Article
  16. The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Review
  17. Article
  18. Impact of meningeal uptake and partial volume correction techniques on [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Article
  19. Article
  20. Multimodal Contrast Agents for Optoacoustic Brain Imaging in Small Animals.Frontiers in bioengineering and biotechnology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

William Charles KreislDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Patrick J LaoDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Aubrey JohnsonDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Zeljko TomljanovicDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Julia KleinDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Krista PollyDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Benjamin MaasDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Krystal K LaingDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Anthony G ChesebroDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Kay IgweDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Qolamreza R RazlighiDepartment of Radiology, Weill Cornell Medicine, New York, NY, USA.
Lawrence S HonigDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Xinyu YanDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.
Seonjoo LeeDepartment of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.
Akiva MintzDepartment of Radiology, Columbia University Irving Medical Center, New York, NY, USA.
José A LuchsingerDepartment of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Yaakov SternDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
D P DevanandDepartment of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
Adam M BrickmanDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Columbia University Irving Medical Center · USInstitute on Aging · USColumbia University · USCornell University · US

Funding

Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Diabetes Status and Brain Amyloid in Middle Aged HispanicsR01AG050440 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LUCHSINGER, JOSE ALEJANDRO · 2015 to 2025
$21.9M
VASCULAR FACTORS AND MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASEP01AG007232 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI MAYEUX, RICHARD P · 1989 to 2008
$21.7M
Exploring Cognitive Aging Using Reference Ability Neural NetworksR01AG038465 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HABECK, CHRISTIAN GEORG, STERN, YAAKOV · 2011 to 2025
$17.0M
Epidemiological and Genetic Investigations of Blood-Based Biomarkers for Alzheimer's Disease in the Multiethnic, Washington Heights, Inwood, Columbia Aging Project (WHICAP)R01AG072474 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, MANLY, JENNIFER JAIE · 2021 to 2025
$13.3M
Imaging of Cognition, Learning and Memory in AgingR01AG026158 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STERN, YAAKOV · 2004 to 2021
$10.9M
Anti-Viral therapy in Alzheimer's diseaseR01AG055422 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DEVANAND, DAVANGERE P · 2017 to 2021
$10.6M
Epidemiology of Biomarkers of Risk and Progression in LOADR01AG037212 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAYEUX, RICHARD P, SCHUPF, NICOLE · 2010 to 2015
$10.1M
Interdisciplinary Research to Understand the Interplay of Diabetes, Cerebrovascular disease and Alzheimers diseaseRF1AG051556 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, LUCHSINGER, JOSE ALEJANDRO · 2015 to 2019
$9.7M
Genetic Epidemiology of Cerebrovascular Factors in Alzheimer's DiseaseRF1AG054023 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAYEUX, RICHARD P · 2016 to 2018
$8.9M
Exploring Cognitive Aging Using Refernce Ability Neural NetworksRF1AG038465 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HABECK, CHRISTIAN GEORG, STERN, YAAKOV · 2016 to 2018
$7.6M
NCATS NIH HHS UL1 TR000040NIA NIH HHS K23 AG052633NIA NIH HHS K24 AG045334NIA NIH HHS K99 AG065506NIA NIH HHS P01 AG007232NIA NIH HHS P50 AG008702NIA NIH HHS R01 AG026158NIA NIH HHS R01 AG037212NIA NIH HHS R01 AG038465NIA NIH HHS R01 AG050440NIA NIH HHS R01 AG055422NIA NIH HHS R01AG055422NIA NIH HHS R01 AG072474NIA NIH HHS RF1 AG038465NIA NIH HHS RF1 AG051556NIA NIH HHS RF1 AG054023NIA NIH HHS RF1 AG058067NIA NIH HHS T35 AG044303
6 · The paper itself

Abstract

introductionPositron emission tomography (PET) imaging for neurofibrillary tau allows investigation of the in vivo spatiotemporal progression of Alzheimer's disease (AD) pathology. We evaluated the suitability of

methodsParticipants (n = 101, 72 ± 9 years, 52% women) underwent amyloid PET, tau PET, structural T1-weighted magnetic resonance imaging, and neuropsychological evaluation. Twenty-one participants had lumbar puncture for CSF measurement of amyloid beta (Aβ)

resultsDISCUSSION:

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersFemaleHumansIsoquinolinesMaleMiddle AgedPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesBiomarkersIsoquinolinesMK-6240tau ProteinsAlzheimer's diseaseamyloid positivitycerebrospinal fluidcognitionMK-6240tau positivitytau positron emission tomography

Identifiers

PMID34057284
PMCPMC8630090
OpenAlexW3000436963

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.